Search results
This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
7 gru 2017 · The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1...
23 wrz 2022 · A total of 2900 premenopausal women with early breast cancer (mean [SD] age at diagnosis, 43.1 [5.6] years) were included in the present analysis (Figure 1; Table 1). At diagnosis, 2088 of 2661 patients (78.5%) had partnered status, and 2498 of 2602 patients (96.0%) had children.
6 dni temu · During follow-up of almost 7 years, hormone-releasing IUD use conferred a 40% higher risk of breast cancer. The data showed a trend toward increasing risk with duration of IUD use,...
2 paź 2024 · The average lifetime risk is approximately 70%, with more than half of all breast cancers in these women occurring before age 50 years. 1 Understanding whether and how use of hormonal contraception (HC) might affect these risks is important for informed decision making.
cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies.
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
